A consortium of investors led a $600m round in Ultima Genomics.

A consortium of investors including General Atlantic, Andreessen Horowitz, D1 Capital, Khosla Ventures, Lightspeed, Marius Nacht, aMoon, and Playground Global, led a $600m round in Ultima Genomics, a biotechnology company. "DNA is nature's storage media and the instruction set for every living organism, yet with current technologies, we can't access that information at the scale needed to truly understand complex biology. Our architecture is intended for radical scaling, and the $100 genome is merely the first example of what it can deliver. We are committed to continuously drive down the cost of genomic information until it is routinely used in every part of the healthcare system," Gilad Almogy, Ultima Genomics Founder and CEO.